EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...

One of the critical applications of OCT is the segmentation of retinal fluids, which can indicate conditions such as diabetic macular edema and age-related macular degeneration. Recent research ...

Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD. Read more to see why I'm ...

Diabetic macular edema (DME) is the leading cause of visual ... which was defined as CMT >300 μm on optical coherence tomography that was caused by intraretinal or subretinal fluid accumulation; ...

A 65-year-old female patient with type 2 diabetes mellitus and hypercholesterolemia ... Optical coherence tomography (OCT) of the fovea showed serous macular detachment and nasally cystoid macular ...

Specifically, in this one, it's a combination of vision and also central subfield thickness changes on the OCT or the presence of a macular ... There has been a small trial that's been done for ...

The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

Susvimo was nonferior to intravitreal ranibizumab based on the change from baseline in distance best corrected visual acuity score. The Food and Drug Administration (FDA) has approved Susvimo ...

The global diabetic macular edema market is on a steady growth trajectory, with an expected valuation of approximately USD 4,120.9 million in 2024. The market is poised to surpass USD 4,642.9 million ...